We are live on ! Find out more
CYTH

Cyclo Therapeutics, Inc. Common Stock
CYTH

Delisted

CYTH was delisted on the 25th of March, 2025.

Back to rankings

12 hedge funds and large institutions have $769K invested in Cyclo Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

3% less capital invested

Capital invested by funds: $795K → $769K (-$26K)

8% less funds holding

Funds holding: 13 → 12 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
+$21.1K
2
TRCT
Tower Research Capital (TRC)
New York
+$4.84K
3
Osaic Holdings
Osaic Holdings
Arizona
+$1.26K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$32.5K
2
Citigroup
Citigroup
New York
-$2K
3
UBS Group
UBS Group
Switzerland
-$2K

CYTH Hedge Fund Activity: Q3 2022 in Review

12 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q3 2022, worth a combined $769K — down 3.3% from $795K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CYTH and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.

The largest buyer was LPL Financial, opening a new position worth an estimated $21.1K. The largest seller was Renaissance Technologies, cutting an estimated $32.5K.

  • 12 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q3 2022, down from 13 in Q2 2022.
  • Funds reported $769K of Cyclo Therapeutics, Inc. Common Stock stock for Q3 2022, down 3.3% quarter-over-quarter.
  • 2 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of -1 holder.
  • The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q3 2022 was LPL Financial, an estimated $21.1K added.
  • The largest Cyclo Therapeutics, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $32.5K sold.

Based on aggregated 13F filings for Q3 2022.